What Is Mazdutide?
Mazdutide is a long-acting peptide medicine that activates two hormone receptors involved in appetite, blood glucose and energy use. These are the glucagon-like peptide-1 receptor, shortened to GLP-1 receptor, and the glucagon receptor. A receptor is a protein that receives a biological signal. A drug that switches a receptor on is called an agonist.
The medicine was developed from oxyntomodulin, a natural gut hormone released after food. Oxyntomodulin can signal through both receptors, but it is removed from the body too quickly to work as a practical weekly medicine. Mazdutide changes the peptide and adds a fatty component so that it remains active for longer.
Mazdutide is no longer simply an early research compound. China's National Medical Products Administration, or NMPA, approved it in 2025 for chronic weight management in eligible adults with overweight or obesity. China also approved it for blood-glucose control in adults with type 2 diabetes. The marketed Chinese name is Xinermei. These approvals do not make mazdutide an approved medicine in the United Kingdom, European Union or United States.
Most published mazdutide trials have enrolled Chinese adults. Those studies provide strong evidence for the populations and products tested, but they do not remove the need for longer safety follow-up or evidence from more varied populations. Our research methodology explains why approval, study design, participant group and duration all affect how confidently findings can be applied.
What kind of molecule is mazdutide?
Mazdutide is a synthetic peptide analogue. A peptide is a chain of amino acids, the small building blocks also used to make proteins. An analogue is a designed molecule that resembles a natural molecule but includes changes intended to improve its medical properties.
Its natural starting point is oxyntomodulin. Cells in the intestine release oxyntomodulin after eating. The hormone can activate both the GLP-1 receptor and glucagon receptor. Natural oxyntomodulin has a short life in the circulation because enzymes break it down and the kidneys remove it. That is useful for a rapidly changing natural signal, but not for a medicine intended to act throughout a week.
Mazdutide is also known by its development codes IBI362 and LY3305677. Eli Lilly and Company, a United States pharmaceutical company, carried out early development under the LY code. Innovent Biologics, a China-based biopharmaceutical company that develops and manufactures medicines, took the programme forward in China. Development codes identify a defined investigational molecule. They should not be treated as a general name for any product marketed as a GLP-1 and glucagon dual agonist.
Public chemical records describe mazdutide as an engineered, acylated peptide. Acylation means attaching a fatty-acid-related chemical group to the peptide. This allows the molecule to associate with albumin, a plentiful blood protein. Albumin association can protect a peptide from rapid enzyme attack and kidney clearance, extending how long it remains in the circulation.
Mazdutide is not semaglutide, tirzepatide, retatrutide or survodutide. Semaglutide mainly activates GLP-1 receptors. Tirzepatide activates GLP-1 and glucose-dependent insulinotropic polypeptide receptors. Retatrutide is designed to activate GLP-1, GIP and glucagon receptors. Survodutide activates the same two broad receptor types as mazdutide, but it has a different peptide design, receptor balance and clinical programme.
How do GLP-1 and glucagon normally work?
GLP-1 is an incretin hormone. Incretins are gut hormones that help the body respond to food. When glucose is raised, GLP-1 supports insulin release from beta cells in the pancreas. Insulin helps move glucose from the blood into tissues and restrains the liver from releasing too much glucose. GLP-1 also reduces glucagon release in some circumstances, slows gastric emptying and acts on brain pathways involved in appetite. Gastric emptying is the movement of food from the stomach into the small intestine.
Glucagon is made by alpha cells in the pancreas. Its traditional role is to protect against low blood glucose. It signals the liver to release stored glucose and make new glucose. This is why activating the glucagon receptor could, in isolation, work against blood-glucose control.
Glucagon signalling has other effects. It can change amino-acid handling, fat metabolism and energy expenditure. Energy expenditure means the energy the body uses to maintain its functions and perform activity. Researchers therefore proposed that carefully balanced GLP-1 and glucagon activity might combine appetite reduction and improved glucose-dependent insulin release with additional effects on energy use and liver fat.
The word balanced matters in a practical, not promotional, sense. Too much glucagon activity could raise blood glucose. Too little might add little beyond a GLP-1 medicine. The clinical trial results show the net effect of the tested mazdutide product. They do not prove that every metabolic change resulted directly from glucagon-receptor activation. Weight loss itself can improve glucose, blood pressure, blood fats and liver markers.
How is mazdutide thought to work?
Mazdutide binds to and activates GLP-1 and glucagon receptors. These receptors belong to a family called G protein-coupled receptors. When activated, they change signals inside a cell, including a messenger called cyclic adenosine monophosphate, or cAMP. The later biological response depends on the tissue and the other signals present.
At the GLP-1 receptor, the expected actions include stronger insulin secretion when glucose is raised, reduced appetite and slower gastric emptying. The glucose-dependent part is important. It means the insulin effect is greater when blood glucose is high, although it does not eliminate low-glucose risk when a medicine is combined with insulin or certain other diabetes drugs.
At the glucagon receptor, the expected actions include changes in liver glucose production, fat processing, amino-acid metabolism and possibly energy expenditure. The liver is central because it expresses many glucagon receptors. Trial reports have described changes in liver enzymes, liver fat and blood lipids, but these remain clinical measurements rather than proof of one isolated molecular route.
Mazdutide is sometimes described as increasing fat burning. This phrase is too simple. A person's change in body fat reflects food intake, energy expenditure, nutrient absorption, metabolic adaptation and the biological effects of weight loss over time. Human trials measure the combined result. They do not show that the medicine selectively burns fat while preserving every other tissue.
The glucagon component also does not make mazdutide glucagon itself. It is one engineered molecule with activity at two receptors. Nor does dual agonism automatically make it better than every single or dual agonist. Products need to be compared in properly designed head-to-head trials using similar participants, treatment periods and analysis methods.
When was mazdutide developed?
The idea of combining GLP-1 and glucagon activity is older than mazdutide. Oxyntomodulin had already shown that one natural peptide could reach both receptors, and research teams spent years trying to make longer-acting analogues with a useful balance of activity.
Mazdutide first appeared in clinical development under the code LY3305677. A first-in-human programme assessed single rising administration levels in healthy volunteers. Published Chinese multiple-ascending-dose research followed under the name IBI362. The name mazdutide was later adopted as the international non-proprietary name, meaning the standard generic name used to identify the active substance.
| Year | Development |
|---|---|
| Before 2019 | Lilly designed LY3305677 as a long-acting oxyntomodulin analogue |
| 2019 to 2020 | Early clinical studies examined safety, movement through the body and initial metabolic effects |
| 2021 | The first full paper on repeated weekly administration in Chinese adults with overweight or obesity was published |
| 2022 | Phase 1b studies reported findings in type 2 diabetes and at higher administration levels in obesity |
| 2023 to 2024 | Randomised Phase 2 studies reported weight and glucose findings in larger Chinese groups |
| 2025 | GLORY-1 Phase 3 results were published; China approved mazdutide for chronic weight management and later for type 2 diabetes |
| 2025 to 2026 | Additional Phase 3 studies examined higher levels, active comparisons and related metabolic conditions |
| September 2026 | Mazdutide remains approved in China but not in the UK, EU or United States |
A Phase 1 trial is the first main stage of human testing and usually focuses on safety, tolerability and pharmacokinetics. Pharmacokinetics describes how a substance enters, moves through and leaves the body. Phase 2 asks whether it appears to work in a target condition and continues safety assessment. Phase 3 tests the medicine in larger groups, often to support regulatory approval. Approval still applies only to the regulator, product and indication named in the authorisation.
How is mazdutide made?
The active substance is not extracted from human or animal tissue. It is manufactured from defined chemical building blocks under controlled conditions. Long therapeutic peptides can be assembled by solid-phase peptide synthesis, by making peptide fragments and joining them, or by a combination of chemical and biotechnology processes. Public articles do not disclose every commercial manufacturing detail for mazdutide.
In solid-phase peptide synthesis, the first protected amino acid is attached to a resin, which is an insoluble polymer support. Further protected amino acids are added in the required order. Protective groups temporarily cover reactive parts of an amino acid so that each step forms the intended peptide bond. The raw materials include protected amino acids, resin, activating chemicals, bases, solvents and reagents used to remove protective groups.
Mazdutide also requires its fatty-acid-related side chain and the chemical linker that joins this group to the selected amino acid in the peptide. Creating the peptide chain is therefore only one part of manufacture. The manufacturer must control the attachment site, linker composition, terminal form and three-dimensional behaviour of the final substance.
The crude material can contain shortened chains, misplaced amino acids, incomplete reactions, altered side chains and residual process chemicals. Preparative high-performance liquid chromatography, shortened to HPLC, can separate many closely related impurities. Mass spectrometry checks molecular mass. Additional tests assess identity, peptide content, water, counterions, residual solvents and degradation products.
Turning the active substance into an approved sterile medicine adds further controls. These include concentration, sterility, bacterial endotoxins, visible and sub-visible particles, container closure, stability and consistency between manufacturing batches. Endotoxins are inflammatory bacterial components that can remain even when living bacteria are absent.
A research-market product using the word mazdutide should not be assumed to be the approved Chinese medicine. A matching label does not establish the same active substance, formulation, strength, sterility, manufacturing controls or regulatory oversight. HPLC purity alone also cannot prove full identity or suitability for human use.
What did the early human studies establish?
The first studies were designed to find out whether repeated exposure was tolerable and whether the intended weekly profile was realistic. Participants were randomly assigned to mazdutide or placebo. Random assignment uses chance to reduce systematic differences between groups. A placebo is a comparison product without the experimental active ingredient, designed to help separate drug effects from changes caused by expectations, study contact and normal variation.
The 2021 multiple-ascending-dose study enrolled Chinese adults with overweight or obesity. Groups received rising weekly administration levels or placebo for 12 weeks. The research found administration-related reductions in body weight and changes in metabolic measurements. Gastrointestinal effects were common, particularly while the level was being increased.
Another Phase 1b trial studied Chinese adults with type 2 diabetes. It measured HbA1c, fasting glucose, body weight and safety. HbA1c reflects the proportion of haemoglobin with glucose attached and estimates average blood glucose over the preceding two to three months. The study supplied an early signal that the glucagon component did not prevent an overall glucose-lowering effect at the tested balances.
A separate early trial explored 9 mg and 10 mg levels over 12 weeks in adults with overweight or obesity. It reported greater short-term weight reductions at the higher tested levels, but small early studies cannot establish the long-term benefit-risk balance. The levels are included here because they document the research. They are not suggested starting points or instructions.
What did the Phase 2 obesity trial find?
The Phase 2 trial enrolled 248 Chinese adults with overweight or obesity. Their average age was 35.5 years, average body weight was 89.4 kg and average body mass index was 31.8 kg/m². Body mass index, shortened to BMI, relates weight to height. It is useful for defining study groups but does not directly measure body fat or individual health.
Participants were assigned to weekly mazdutide groups with target levels of 3 mg, 4.5 mg or 6 mg, or to placebo. Neither participants nor most investigators knew which treatment had been assigned. This is called double blinding and helps reduce biased reporting and assessment. The treatment period lasted 24 weeks.
Average weight change at week 24 was about minus 6.7 per cent in the 3 mg group, minus 10.4 per cent in the 4.5 mg group and minus 11.3 per cent in the 6 mg group, compared with about plus 1.0 per cent with placebo under the trial's stated analysis. The trial also reported improvements in waist circumference and several cardiometabolic measurements. Cardiometabolic refers to factors linked with both cardiovascular disease and metabolism, such as blood pressure, glucose and blood lipids.
These were group averages. Individuals varied, and the 24-week study could not show how durable the changes would be over several years. The participants were Chinese adults and did not have diabetes, so the findings should not be silently transferred to every population or clinical situation.
What did the US Phase 2 trial add?
A separate Phase 2 trial enrolled 179 adults without type 2 diabetes at 24 US centres. Participants were randomly assigned to three mazdutide groups or placebo in a double-blind study lasting 48 weeks. The paper appeared online on 21 August 2026 and in the November journal issue; its issue date should not be mistaken for a new November trial result.
At the main 32-week assessment, average weight changes were −7.3%, −15.6% and −18.1% across mazdutide groups versus −0.9% with placebo. These used an efficacy estimand, a hypothetical estimate under specified treatment assumptions. Further reductions occurred by week 48. Gastrointestinal effects were most common; 20% of the highest-level group discontinued because of adverse events.
The trial extends evidence beyond Chinese populations, but its small groups cannot establish rare-event safety or universal effectiveness. Its higher experimental levels should not be confused with approved Chinese product conditions or personal dosing guidance. US research does not itself establish US approval.
What did GLORY-1 find?
GLORY-1 was the main Phase 3 weight-management trial supporting the first approval. It enrolled 610 Chinese adults aged 18 to 75. Participants had obesity, defined in the trial as BMI of at least 28 kg/m², or overweight with at least one related health problem. The BMI thresholds used in Chinese clinical practice differ from some European and United States thresholds.
Participants were assigned in roughly equal numbers to weekly mazdutide with target levels of 4 mg or 6 mg, or placebo. Everyone also received lifestyle support. The first main assessment was at 32 weeks, with follow-up to 48 weeks.
Under an efficacy estimand, which estimates the effect if participants remained on their assigned treatment without certain events interfering, average weight change at week 32 was minus 10.97 per cent with 4 mg, minus 13.38 per cent with 6 mg and minus 0.24 per cent with placebo. At week 48, the corresponding changes were minus 12.05 per cent, minus 14.84 per cent and minus 0.47 per cent.
At week 32, 76.3 per cent of the 4 mg group and 84.0 per cent of the 6 mg group had lost at least 5 per cent of starting body weight, compared with 10.9 per cent of the placebo group. At week 48, 37.0 per cent and 50.6 per cent of the mazdutide groups had lost at least 15 per cent, compared with 2.1 per cent with placebo.
An estimand is the exact treatment effect a trial is designed to estimate. Another analysis, called a treatment-policy estimand, includes outcomes regardless of whether treatment was stopped or other specified events occurred. Its weight reductions were somewhat smaller. Reporting which analysis produced a number prevents a best-case figure from being presented as though it described every participant's real-world result.
The trial lasted 48 weeks. It therefore provides much stronger evidence than an uncontrolled before-and-after report, but it does not answer what happens after many years, after treatment stops or in populations not well represented in the study.
What evidence exists in type 2 diabetes?
Type 2 diabetes is a long-term condition in which blood glucose remains too high because the body does not respond adequately to insulin and may not produce enough insulin for its needs. Mazdutide has been studied both on its own and against established glucose-lowering medicines.
A Phase 2 trial assigned Chinese adults with type 2 diabetes to different mazdutide levels, dulaglutide or placebo. Dulaglutide is an approved weekly GLP-1 receptor medicine used as an active comparison. An active comparison helps show how an investigational treatment performs against a medicine rather than only against no active drug.
The DREAMS-1 Phase 3 trial studied 320 adults whose type 2 diabetes was not adequately controlled by diet and exercise alone. Participants received weekly mazdutide at target levels of 4 mg or 6 mg, or placebo, for 24 weeks, followed by an extension. Average starting HbA1c was 8.24 per cent.
At week 24, HbA1c fell by 1.57 percentage points in the 4 mg group and 2.15 points in the 6 mg group, compared with 0.14 points with placebo. Average body weight changed by minus 5.61 per cent, minus 7.81 per cent and minus 1.26 per cent respectively. The percentage-point wording matters. A fall from 8.2 to 6.2 per cent is a fall of 2.0 percentage points, not a 2 per cent relative reduction.
Further Phase 3 studies compared mazdutide with dulaglutide and semaglutide in Chinese adults. Those comparisons are important, but direct trial findings should be read with the target levels, participant characteristics, blinding and analysis plan in view. Results from a company announcement are less complete than a full peer-reviewed report because they do not expose every method and outcome to the same scrutiny.
What do the higher-level studies add?
Higher administration levels have been explored in people with more severe obesity. A 20-week early trial studied schedules intended to reach 16 mg. It enrolled only 32 adults and was designed mainly to examine safety and tolerability. Large changes in a small, short trial can be interesting, but they should not be treated as equal to a large Phase 3 result.
GLORY-2 tested a 9 mg target in Chinese adults with moderate to severe obesity. The company reported that the study met its main and key secondary outcomes, with substantial mean weight reduction over 60 weeks. A later peer-reviewed publication provides a stronger basis for interpreting the result than the first company announcement. Even then, the study level should not be turned into a personal recommendation.
These programmes help researchers ask whether the response continues at higher exposure and whether adverse effects or treatment withdrawals also rise. More is not automatically better. A useful medicine needs a level at which added benefit justifies added harm for the approved group.
What are the known safety findings?
The most frequent adverse events in mazdutide trials were gastrointestinal. Adverse event is the research term for an unwanted medical occurrence during a study, whether or not investigators judge that the treatment caused it. Commonly reported events included nausea, diarrhoea, vomiting, reduced appetite and abdominal symptoms. Many were mild or moderate and occurred while administration levels were increasing.
Some participants stopped treatment because of adverse effects. Withdrawal matters because a medicine cannot deliver its intended long-term benefit if a person cannot continue it. Trial averages can also look more favourable when an analysis estimates what would have happened had everyone remained on treatment, so both efficacy and treatment-policy analyses deserve attention.
Heart rate increased in some studies. Glucagon and GLP-1 pathways can affect the cardiovascular and autonomic systems, but a change in pulse does not by itself establish long-term harm or safety. Dedicated outcome studies and longer exposure are needed to assess uncommon cardiovascular events.
Gallbladder disease, pancreatitis, severe gastrointestinal disease and low blood glucose are important areas for medicines with GLP-1 activity. Pancreatitis is inflammation of the pancreas. Risk in an individual depends on the approved product information, medical history and other medicines. Low blood glucose is particularly relevant when an incretin medicine is combined with insulin or a sulfonylurea, a class of tablets that can drive insulin release.
Animal and class warnings cannot simply be copied to a new medicine without checking its authorised Chinese label. Equally, the absence of a frequent signal in a trial does not prove that a rare event cannot occur. Trials are powered to measure common outcomes more readily than very rare harms.
Pregnancy, breastfeeding, severe liver or kidney disease and use in children require product-specific evidence. The first adult approvals do not establish safety for these groups. The guide therefore does not infer advice beyond the populations studied and authorised.
Does mazdutide protect the heart, kidneys or liver?
Mazdutide trials have reported improvements in several risk markers, including waist circumference, blood pressure, triglycerides, liver enzymes, uric acid and estimated liver fat. A biomarker is a measurement that may reflect a biological process or risk. A biomarker improvement can be useful, but it is not automatically proof that fewer heart attacks, strokes, cases of kidney failure or liver-related events will occur.
For example, alanine aminotransferase, shortened to ALT, is an enzyme measured in blood. A fall can be consistent with improved liver health, but ALT can change for several reasons and cannot stage liver scarring by itself. Magnetic resonance imaging can estimate liver fat more directly, yet lower liver fat is still not identical to showing fewer cases of cirrhosis or liver failure.
Cardiovascular outcome trials are designed around events such as cardiovascular death, heart attack and stroke. Until those event data exist for mazdutide, it is more accurate to say that trials improved selected risk factors than to claim that the drug prevents cardiovascular disease.
How does mazdutide compare with semaglutide, tirzepatide and survodutide?
Mechanism alone cannot rank these medicines. Semaglutide has extensive global approval and cardiovascular outcome evidence. Tirzepatide has large international Phase 3 programmes and activates GIP as well as GLP-1 receptors. Mazdutide adds glucagon-receptor activity and has Chinese approvals. Survodutide also activates GLP-1 and glucagon receptors but has a different molecular design and remains investigational as of this review.
Trial percentages from separate studies should not be placed side by side as though the studies were one race. Participants may differ in average weight, diabetes status, ethnicity, lifestyle support, follow-up, target level, missing-data method and the estimand used. A head-to-head trial randomises comparable participants within the same protocol and is therefore more informative.
Mazdutide has been compared with semaglutide and dulaglutide in Chinese Phase 3 programmes. Those trials improve the comparison, but the precise question still matters. A study in adults with type 2 diabetes and obesity does not automatically answer which medicine is best for a person without diabetes, established cardiovascular disease or a different background treatment.
What remains uncertain?
The central efficacy findings are no longer based only on small early trials. Mazdutide has randomised Phase 3 evidence and regulatory approval in China. The remaining questions concern breadth, duration and outcomes.
- Most published participants were Chinese adults. More evidence is needed across ethnic groups, healthcare systems and patterns of accompanying disease.
- Trials lasting months to just over a year cannot define effects over many years.
- Weight regain after stopping treatment needs careful study.
- Cardiovascular, kidney and liver clinical outcomes require event-focused trials, not only biomarkers.
- Higher administration levels may add weight reduction, adverse effects or both.
- Real-world adherence may differ from closely supported clinical trials.
- Approval in one jurisdiction does not establish approval, availability or identical labelling elsewhere.
These are normal questions for a relatively new medicine. They do not cancel the Phase 3 results, but they set the boundary around what those results can prove.
Is mazdutide legal or approved in the UK, EU and United States?
As reviewed in September 2026, mazdutide is an approved medicine in China for chronic weight management and type 2 diabetes. It is not an MHRA-approved medicine in the United Kingdom, an EMA-authorised medicine in the European Union or an FDA-approved medicine in the United States.
The absence of local approval is not a claim that the molecule has no evidence. It means the relevant regulator has not authorised a mazdutide product for routine supply under its own system. A product sold online with the same name is not converted into an approved medicine by the existence of a Chinese authorisation.
People should also not assume that a compounded or research-labelled product has been assessed as equivalent to Xinermei. Equivalence requires far more than the same stated ingredient. It includes identity, strength, impurities, formulation, sterile manufacture, stability and clinical oversight.
Frequently asked questions
Is mazdutide a peptide?
Yes. It is a synthetic peptide analogue modelled on oxyntomodulin and chemically modified to remain active for longer.
Is mazdutide the same as Ozempic or Wegovy?
No. Ozempic and Wegovy contain semaglutide, which mainly activates the GLP-1 receptor. Mazdutide activates GLP-1 and glucagon receptors.
Is mazdutide the same as survodutide?
No. Both are GLP-1 and glucagon receptor dual agonists, but they are different molecules with different receptor balances, trial programmes and regulatory positions.
Is mazdutide approved?
It is approved in China for chronic weight management and type 2 diabetes. It is not approved in the UK, EU or United States as of September 2026.
What is Xinermei?
Xinermei is the marketed Chinese brand name reported for the approved mazdutide medicine.
What does dual agonist mean?
It means one molecule activates two receptor types. For mazdutide, those are the GLP-1 receptor and glucagon receptor.
What is HbA1c?
HbA1c measures the proportion of haemoglobin with glucose attached. It provides an estimate of average blood glucose over roughly two to three months.
What was GLORY-1?
GLORY-1 was a 610-participant Chinese Phase 3 trial that compared weekly mazdutide with placebo for weight management, with follow-up to 48 weeks.
Does mazdutide cause weight loss?
Randomised trials found greater average weight reduction with the tested mazdutide regimens than with placebo. Individual results varied, and the findings do not provide personal treatment instructions.
Does mazdutide treat fatty liver disease?
Trials have reported reductions in liver fat and liver-related biomarkers, but an improvement in these measurements is not the same as an approved indication or proof that the medicine prevents cirrhosis or liver failure.
Are the trial administration levels recommended dosages?
No. They document what researchers tested. Approved prescribing belongs to the authorised product information and a qualified clinician in the relevant jurisdiction.
Can a research product be assumed to match approved mazdutide?
No. A matching name does not establish the same molecule, purity, formulation, sterility, stability or regulatory oversight.
Bottom line
Mazdutide is one of the clearest examples of a research peptide becoming a regulated medicine. It is a long-acting oxyntomodulin analogue that activates GLP-1 and glucagon receptors. Large Chinese trials found meaningful average reductions in body weight and HbA1c, and China approved the medicine for weight management and type 2 diabetes in 2025.
The evidence still needs boundaries. Most published participants were Chinese, longer-term outcome data remain limited and approval has not extended to the UK, EU or United States. Gastrointestinal adverse effects are common, while the long-term balance of cardiovascular, liver, kidney and uncommon safety outcomes continues to be studied.
Mazdutide should therefore be described as an approved Chinese medicine with substantial human evidence, not as a globally approved product, a guaranteed weight-loss result or a generic name that validates unrelated research-market material.
Sources
Research reviewed through 2 November 2026.